CASI Pharmaceuticals' substantial miss on both earnings per share and revenue, compared to estimates and previous year's performance, suggests a negative outlook for the company's financial health. This could lead to a decrease in investor confidence and a potential drop in stock price in the short term, especially considering the historical context of share price decline following earnings misses.